Abstract: High-altitude pulmonary hypertension (HAPH) is a severe complication arising from an inability to acclimatize to high altitude, associated with significant morbidity and mortality. This study aimed to analyze the effects of macitentan, selexipag, riociguat, and reoxygenation on HAPH using a rat model. While selexipag, macitentan, and reoxygenation successfully prevented increases in mean pulmonary artery pressure (mPAP) and right ventricular hypertrophy, riociguat showed minimal efficacy. Integrated RNA-seq and proteomic analysis identified Serpina1, Cryz, and Cmc1 as key genes involved in HAPH, offering new insights for future targeted drug development.
The Challenge of High-Altitude Pulmonary Hypertension
HAPH affects millions of people living at or visiting elevations above 2,500 meters. Unlike other forms of pulmonary hypertension, HAPH is triggered specifically by chronic hypobaric hypoxia, which causes pulmonary artery constriction and right ventricular hypertrophy. While several drugs exist for standard pulmonary arterial hypertension (PAH), their effectiveness for the high-altitude variant is not well-established. This research sought to determine which existing drugs are effective for HAPH and to identify the underlying molecular drivers of the disease.
Methodology
Researchers utilized a Sprague-Dawley rat model, subjecting the animals to a hypobaric hypoxia chamber for 35 days to induce HAPH. Starting at day 21, four interventions were tested:
- Selexipag: A prostacyclin receptor agonist.
- Macitentan: An endothelin receptor antagonist.
- Riociguat: A soluble guanylate cyclase (sGC) stimulator.
- Reoxygenation: Returning the rats to normal oxygen levels.
To map the cellular response, the study employed a multi-omics pipeline combining transcriptomics (RNA-seq) and proteomics (LC-MS/MS) on lung and heart tissues. Bioinformatics tools, including Weighted Gene Co-expression Network Analysis (WGCNA), were used to identify molecular features that best predicted a successful therapeutic response.
Physiological Impacts of Treatment
The study revealed significant differences in drug efficacy. Selexipag, macitentan, and reoxygenation effectively reduced mean pulmonary artery pressure (mPAP) and the Right Ventricular Hypertrophy Index (RVHI). Notably, riociguat had almost no effect on these physiological markers in this specific model.
Multi-Omics Analysis and Key Targets
By integrating RNA and protein datasets, the researchers filtered out biological "noise" to identify three hub genes as critical to HAPH development and recovery:
- Serpina1: A protease inhibitor that protects lung tissue from damage.
- Cryz (Crystallin Zeta): An mRNA stabilizer that may help cells manage metabolic stress.
- Cmc1: A chaperone protein essential for the assembly of mitochondrial complexes, suggesting that HAPH is deeply tied to mitochondrial energy failure.
The molecular responses to selexipag and macitentan were remarkably similar, suggesting they converge on the same downstream therapeutic pathways. GO-enrichment analysis further revealed that differentially expressed genes were primarily involved in metabolic regulation, transcription, and translation.
Discussion and Future Directions
The findings highlight that HAPH involves a massive metabolic and structural re-wiring of tissue, involving pathways such as HIF-1, Notch, and Wnt signaling. While the rat model effectively simulates altitude, the study's primary limitation is the lack of direct "loss-of-function" experiments (like CRISPR knockouts) to prove that modulating these genes directly cures HAPH. Future research should focus on validating Serpina1, Cryz, and Cmc1 in human clinical samples and developing specific compounds to target these pathways.
Summary updated